ALAMEDA, Calif.--(BUSINESS WIRE)--Advanced Cell Technology, Inc. (OTCBB:ACTC) Chairman and CEO William Caldwell today commented on the midterm United States Congressional elections held Tuesday, November 7, 2006. “Embryonic stem cells hold the potential to provide a well-characterized and reproducible source of replacement cells for clinical studies and the treatment of devastating diseases and injuries such as heart disease, cancer, macular degeneration, Parkinson’s disease, Alzheimer’s disease, and diabetes. We have been encouraged by our progress to date, though there is little doubt that in the United States progress in our field has been hampered by the ban on federal funding of research on new embryonic stem cell lines. I believe the changing political tide brings us yet another step closer to federal funding for embryonic stem cell research and ultimately to developing therapies for devastating and life threatening indications.”
